维奈克拉联合阿扎胞苷与强化化疗治疗新诊断急性髓系白血病的比较
该回顾性研究比较了维奈克拉联合阿扎胞苷(ven/aza,n=143)与强化化疗(IC,n=149)在新诊断急性髓系白血病(AML)患者中的疗效。
要点
- RUNX1突变、高龄、继发性AML等因素倾向支持选择ven/aza而非IC。
核心结论
- 接受IC的患者总生存优于接受ven/aza的患者,但在倾向性匹配的等效基线队列中,ven/aza显示出有利的OS趋势。
- 特定变量如RUNX1突变可帮助识别更可能从ven/aza或IC中获益的患者,从而指导治疗决策。
研究设计与样本
- 回顾性分析新诊断AML患者,ven/aza组143例,IC组149例,比较结局并探索预测治疗反应的变量。
主要发现
- 总体缓解率:ven/aza组76.9%,IC组70.5%。
- 倾向ven/aza反应的变量包括高龄、继发性AML和RUNX1突变;AML M5倾向支持IC。
- 在匹配队列中,高龄、不良风险和RUNX1突变倾向支持ven/aza,而中危倾向支持IC。
关键数值与推荐
- 缓解率:ven/aza 76.9%,IC 70.5%。
临床怎么用
- 对于可能适合IC或ven/aza的患者,可根据年龄、AML类型、风险分层及RUNX1突变等变量个体化选择治疗方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Venetoclax (ven) plus azacitidine (aza) is the standard of care for patients with newly diagnosed acute myeloid leukemia (AML) who are not candidates for intensive chemotherapy (IC). Some patients who are IC candidates instead receive ven/aza. We retrospectively analyzed patients with newly diagnosed AML who received ven/aza (n = 143) or IC (n = 149) to compare outcomes, seek variables that could predict response to 1 therapy or the other, and ascertain whether treatment recommendations could be refined. The response rates were 76.9% for ven/aza and 70.5% for IC. The median overall survival (OS) was 884 days for IC compared with 483 days for ven/aza (P = .0020). A propensity-matched cohort was used to compare outcomes in the setting of equivalent baseline variables, and when matched for age, biological risk, and transplantation, the median OS was 705 days for IC compared with not reached for ven/aza (P = .0667). Variables that favored response to ven/aza over IC included older age, secondary AML, and RUNX1 mutations. AML M5 favored response to IC over ven/aza. In the propensity-matched cohort analyzing OS, older age, adverse risk, and RUNX1 mutations favored ven/aza over IC, whereas intermediate risk favored IC over ven/aza. In conclusion, patients receiving IC have improved OS compared with those receiving ven/aza. However, in a propensity-matched cohort of patients with equivalent baseline factors, there was a trend toward favorable OS for ven/aza. Specific variables, such as RUNX1 mutations, reported here for the first time, can be identified that favor ven/aza or IC, helping to guide treatment decisions for patients who may be eligible candidates for either therapy.
引用
- Cherry EM, Abbott D, Amaya M, et al. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Blood Adv. 2021. PMID: 34610123. doi:10.1182/bloodadvances.2021005538
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。